Corvus Pharmaceuticals, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Corvus Pharmaceuticals, Inc. (CRVS) had Lessee, Operating Lease, Liability, to be Paid, Year One of $1.43 million as of 2023-12-31, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2024-11-12
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $1.43M.
- 2022-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $325.00K.
- 2022-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $650.00K.
- 2022-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $975.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2023-12-31 | $1.43M 10-Q · filed 2024-11-12 |
| 2022-09-30 | $325.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $650.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $975.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.30M 10-Q · filed 2022-11-03 |
| 2021-09-30 | $1.30M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $1.30M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $1.30M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $1.26M 10-K · filed 2022-03-10 |
| 2019-12-31 | $1.16M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |